A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
Sponsor study identifier
interventional
300
3 countries
32
Study Start
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2006
Actual (reported)Study Completion
August 2006
Actual (reported)The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
November 5, 2004
Actual (reported)November 8, 2004
Actual (reported)August 2006
Actual (reported)August 2006
Actual (reported)Comparison of weight change from baseline to Week 16 in patients with schizophrenia or schizoaffective disorder treated with aripiprazole or olanzapine
Assessment of metabolic laboratory measures
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Local Institution
Little Rock, Arkansas, United States
Local Institution
Anaheim, California, United States
Local Institution
Cerritos, California, United States
Local Institution
Garden Grove, California, United States
Local Institution
National City, California, United States
Local Institution
San Diego, California, United States
Local Institution
New Britain, Connecticut, United States
Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008 Jul;69(7):1046-56. doi: 10.4088/jcp.v69n0702.
Bristol-Myers Squibb
Bristol-Myers Squibb
First Submitted
November 5, 2004
First Posted
November 8, 2004
Study Start
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2006
Actual (reported)Aripiprazole Open-Label, Safety and Tolerability Study
Local Institution
North Miami, Florida, United States
Local Institution
Augusta, Georgia, United States
Local Institution
Macon, Georgia, United States
Local Institution
Hoffman Estates, Illinois, United States
Local Institution
Louisville, Kentucky, United States
Local Institution
Glen Burnie, Maryland, United States
Local Institution
Haverhill, Massachusetts, United States
Local Institution
Worcester, Massachusetts, United States
Local Institution
Minneapolis, Minnesota, United States
Local Institution
Brooklyn, New York, United States
Local Institution
Nashville, Tennessee, United States
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
DeSoto, Texas, United States
Local Institution
San Antonio, Texas, United States
Local Institution
Wauwatosa, Wisconsin, United States
Local Institution
Goibnia, Goiás, Brazil
Local Institution
Belo Horizonte, Minas Gerais, Brazil
Local Institution
Rio de Janeiro, Rio de Janeiro, Brazil
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Botucatu, São Paulo, Brazil
Local Institution
Sao Paulo - Sp, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
Exeter, Devon, United Kingdom
Local Institution
Birmingham, West Midlands, United Kingdom
Study Completion
August 2006
Actual (reported)Last Updated
November 11, 2013
Record last verified: 2008-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: